Citalopram: An interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype

Pharmacopsychiatry

Volumn 32, Issue 6, 1999, Pages 232-234

  Haffen, Emmanuel ^a   Vandel, P ^a   Broly, F ^b   Vandel, S ^a   Sechter, D ^a   Bizouard, P ^a   Bechtel, P R ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYNORCLOMIPRAMINE; ALPRAZOLAM; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; DRUG METABOLITE; NORCLOMIPRAMINE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; ZOPICLONE;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; OBSESSION; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PHENOTYPE;

EID: 0032735297     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-1999-7960     Document Type: Article

References (21)

1. Nielsen K-K, Brosen K: High performance liquid chromatography of clomipramine and metabolites in human plasma and urine. Ther. Drug Monit. 1993; 15: 122-128
2. Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Lo Guidice L, et al: An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 1995; 5: 373-384
3. Baumann P, Jonzier-Perey M: GC and GC-MS procedure for simultaneous phenotyping with dextromethorphan aud mephenytoin. Clin. Chim. Acta 1988; 171: 211-222
4. Baumann P, Meyer J-W, Amey M, Baettig D, Bryois D, Jonzier-Perey M, et al: Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther. Drug Monit. 1992; 14: 1-8
5. Barr L-C, Goodman W-K, Anand A, McDougle C-J, Price L-H: Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive compulsive disorder. Am. J. Psychiatry 1997; 154: 1293-1295
6. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 1996; 31: 444-469
7. Preskorn SH: Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinet. 1997; 32(s): 1-21
8. Crewe H-K, Lennard M-S, Tucker G-T, Woods F-R, Haddock R-E: The effect of selective serotonin reuptake inhibitors on cytochrome P450 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol. 1992; 34: 262-265
9. Ereshefsky L, Riesenman C, Lam YWF: Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin. Pharmacokinet. 1995; 29(s): 10-19
10. Rochat B, Amey M, Gillet M, Meyer U-A, Baumann P: Identification of three cytochromes P450 involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997; 7: 1-10
11. Sindrup S-H, Brosen K, Hansen M-G, Aaes-Jorgensen T, Overo K-F, Cram L-F: Pharmacokinetics of citalopram in relation to the sparteine and mephenytoin oxidation polymorphisms. Ther. Drug Monit. 1993; 15: 11-17
12. Valoti M, Frosini M, Palmi M, De Matteis F, Sgaragli G: N-dealkylation of chlorimipramine and chlorpromazine by rat liver microsomal cytochrome P450 isozymes. J. Pharm. Pharmacol. 1998; 50: 1005-1011
13. Nielsen K-K, Brosen K, Hansen M-G-J, Gram L-F: Single-dose kinetics of clomipramine: Relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin. Pharmacol. Ther. 1994: 55: 518-527
14. Baettig D, Bondolfi G, Montaldi S, Amey M, Baumann P: Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. Eur. J. Clin. Pharmacol. 1993; 44: 403-405
15. Leinonen E, Lepola U, Koponen H, Kinnunen I: The effect of age and concomittant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther. Drug Monit. 1996; 18: 111-117
16. Jeppesen U, Gram L-F, Vistisen K, Loft S, Poulsen H-E, Brosen K: Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 1996; 51: 73-78
17. Lepola U, Leinonen E, Koponen H: Increased serum drug concentrations in concomitant treatment with citalopram, clomipramine and alprazolam. Eur. Psychiatry 1994: 9: 312-314
18. Gram L-F, Hansen M-G-J, Sindrup S-H, Brosen K, Poulsen J-H, Aaes-Jorgensen T, et al: Citalopram: Interaction studies with levomepromazine, imipramine and lithium. Ther. Drug Monit. 1993; 15: 18-24
19. Morgan ET, Sewer MB, Iber H, Gonzalez FJ, Lee YH, Tukey RH, Okino S, Vu T, Chen YH, Sidhu JS, Omiecinski CJ, Anthony YH: Lu commemorative issue. Physiological and pathophysiological regulation of cytochrome P450. Drug Met. Disp. 1998; 26: 1232-1240
20. Koytchef R, Alken R-G, Vlahov V, Kirrov V, Kaneva R, Thyroff-Friesinger U, et al: Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metaprolol. Eur. J. Clin. Pharmacol. 1998; 54: 469-474
21. Griese E-U, Zanger U-M, Brudermanns U, Gaedigk A, Mikus G, Morike K, et al: Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a german population. Pharmacogenetics 1998; 8: 15-26